Abstract
Objective: This study was intended to provide data to support the effect of Shashen Maidong Decoction in improving mycoplasma pneumonia in pediatric patients through systematic evaluation. Methods: PubMed, the Web of Science, EMbase, CNKI, CQVIP, Wan-Fang, and CBM databases were comprehensively searched from established in June 2021. Randomized controlled trials of TRQI were selected by screening the literature and extracting information. The Cochrane RCT Evaluation Manual was used to evaluate the methodological quality of all included studies, and Meta-analysis was performed using Stata 14.0 and Review Manager 5.4 software. Results: A total of 1,127 patients from 12 clinical studies met the inclusion criteria. Meta-analysis results showed that the treatment group of Shashen Maidong Decoction was able to significantly increase the overall efficiency level and significantly reduce the incidence of adverse reactions, time for disappearance of cough, time for relief of cough, time for defervescence, time for disappearance of lung rales, time for return to normal of chest X-ray, T lymphocyte subpopulation (CD3+) and tumor necrosis factor-α (TNF-α) and other index levels (p < 0.05). Conclusion: Shashen Maidong Decoction has a significant improvement in the levels of relevant indexes in pediatric mycoplasma pneumonia, which provides a basis for the safety and efficacy of pediatric mycoplasma pneumonia. However, due to the small sample size included in the study, the study quality was not high, and more randomized controlled trials of high quality are required for further validation.
Highlights
Mycoplasma pneumoniae (MP) is one of the most common causes of community-acquired pneumonia (CAP) in children, and studies have shown that the incidence of pediatric mycoplasma pneumonia (MPP) accounts for approximately 25% of all CAP (Lee et al, 2018; Jain et al, 2015; Wang, 2017)
Shashen Maidong Decoction has a significant improvement in the levels of relevant indexes in pediatric mycoplasma pneumonia, which provides a basis for the safety and efficacy of pediatric mycoplasma pneumonia
A total of 12 clinical studies were included, and a total of 1,127 patients with mycoplasma pneumonia were treated with Shashen Maidong Decoction (SMD), and the levels of total effective rate, time to disappearance of cough, time to relief of cough, time to fever reduction, time to chest film normalization, T lymphocyte subpopulation (CD3+) and tumor necrosis factor-α (TNF-α) were analyzed, and the results showed that the clinical efficacy of the observation group treated with SMD was significantly The results showed that the clinical efficacy of the observation group treated with SMD was significantly better than that of the control group, and the levels of all indexes analyzed were statistically significant
Summary
Mycoplasma pneumoniae (MP) is one of the most common causes of community-acquired pneumonia (CAP) in children, and studies have shown that the incidence of pediatric mycoplasma pneumonia (MPP) accounts for approximately 25% of all CAP (Lee et al, 2018; Jain et al, 2015; Wang, 2017). MP is a highly evolved and polymorphic bacterial pathogen without a cell wall (Guo et al, 2019). It has a wide range of clinical manifestations, including upper respiratory tract infections, pneumonia, and extrapulmonary manifestations (such as encephalitis) (Kutty et al, 2019). Macrolide antibiotics (MA) such as azithromycin (AZM) are preferred in Western medicine for the treatment of pediatric MMP (Ni, 2019), epidemiological results in recent years have shown that resistant MP strains of macrolides are increasing year by year, leading to an increase in the number of critically ill and refractory patients or a prolonged course of disease (Wu and Wu, 2016). The effectiveness of TCM in the treatment of mycoplasma pneumonia has been shown (Shi and Yang, 2019), such as Yangyin Qingfei Decoction (YYQFD) (Lin, 2020) and Shaoyao
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
